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Background
Immunotherapy for breast cancer is now being seriously
considered, despite past beliefs that this cancer type was
non-immunogenic. Immune profiling has been variably
associated with outcome, but standard techniques have
greatly limited interpretation. These studies examine
immune profiling of breast cancer patients using high-
sensitivity methods in relation to clinical outcome.
Methods
High-sensitivity detection and analysis methods were
used to determine Immune Profiles of female human
breast cancer in Tumour Infiltrating Leukocytes (TIL) in
longitudinal cohort comparative outcome studies.
Results
Immune profiles showed predominantly CD3, CD4,
CD45RO TIL with low/absent IL-2a receptor expression.
However, these were significantly correlated to 5- and
10-year survival times.
Conclusions
Immune profiling of the TIL infiltrate in human breast car-
cinoma using high-sensitivity detection and analysis techni-
ques showed predominance of CD3 cells, being ab-TCR,
CD4 T cells of mainly memory phenotype. Importantly,
these findings were strongly predictive of 5- and 10-year
survival. This indicates the real possibility that TIL infiltra-
tion in breast cancer might be open to immunological
manipulation therapeutically to improve clinical outcome.
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